Bcl—2和nm23蛋白在上皮性卵巢中的表达及其临床意义

采用免疫组织化学技术，对４５例上皮性卵巢癌组织中ｂｃｌ－２、ｎｍ２３蛋白的表达状况进行研究。结果示，ＢＣＬ－２蛋白的阳性表达率为６０％，其表达与组织学分级有关，ｎｍ２３蛋白的阳性表达率为４０％，其表达与临床分期有关。提示，对这两个指标的检测有利行估计卵巢癌病人的预后。

Expressions and their clinical significance of bcl-2 and nm23 in epithelial ovarian carcinoma]

The expressions of bcl-2 and nm23 protein in epithelial ovarian carcinoma were analyzed by immunohistochemical method. The results were that 1. the positive expression of bcl-2 protein was 60% (27/45) in epithelial carcinoma; the positive expression of bcl-2 protein in Grade I was 31.25% (5/16), in Grade II 57.14% (8/14), in Grade III 93.33% (14/15) and there were significant differences among them (P < 0.05); 2. the positive expression of nm23 protein was 40% (18/45) in epithelial carcinoma; the positive expression of bcl-2 protein in Stage I/II was 57.1% (12/21), in Stage III/IV 25% (6/24), and there was significant difference between them (P < 0.05). We conclude that the expressions of bcl-2 and nm23 protein are associated with tumor differentiation and clinical stage respectively. Analyzing the expressions of bcl-2 and nm23 are beneficial to the prognosis of the ovarian tumor patients.